🧬 Trust Over Control: Building Teams Like the Best Scientists | Roy Maute (Part 3/4)

What It Covers

Roy Maute traces his path from co-founding Ab Initio Biotherapeutics — a 10-person yeast-display drug discovery startup with a Pfizer collaboration — through its acquisition by Ligand Pharmaceuticals, then joining 47 Inc before its $4.9 billion Gilead acquisition, extracting management and collaboration lessons across each transition.

Key Questions Answered

• •Trust-based hiring over micromanagement: Irving Weissman's lab model — recruit through trusted networks, then grant full autonomy — produces exceptional output from top scientists who only need space, equipment, and funding. When building a team, identify which hires are self-directed and remove supervisory friction entirely rather than applying uniform oversight to everyone.
• •Goal-setting framing for teams: Rather than sandbagging estimates to guarantee delivery, set the most aggressive realistic targets openly and track progress transparently together. This prevents the "say four months, mean two" dynamic that erodes ambition. Psychological safety around missing goals — not sandbagging — is the mechanism that makes honest, stretch-oriented goal-setting sustainable.
• •Collaboration credibility through warm introductions: The Pfizer collaboration at Ab Initio became possible only because Tim Springer, a respected scientist-entrepreneur, made the introduction. Cold outreach to large pharma rarely works at seed stage; instead, map your founding team's academic network for connectors who carry credibility with industry partners and can transfer that trust to your company.
• •Startup speed as structural advantage: Large organizations like Gilead struggle with option paralysis — abundant resources make prioritization harder, not easier. Early-stage startups with a single drug and target avoid this by default. Founders should treat narrow focus as a deliberate competitive asset, not a resource limitation, particularly during preclinical and early clinical development phases.
• •Watch-one-do-one-teach-one for non-scientific skills: Roy absorbed acquisition mechanics, clinical biomarker strategy, and large-pharma governance primarily by observation before executing. Deliberately position yourself inside processes — even without a formal role — to compress learning cycles. One acquisition observed closely provides more applicable knowledge than multiple secondhand accounts from advisors or reading.